Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. CDN Services

We are analyzing https://link.springer.com/article/10.1186/1471-2407-7-59.

Title:
Enhanced NFκB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer | BMC Cancer
Description:
Background Signaling pathways that converge on two different transcription factor complexes, NFκB and AP-1, have been identified in estrogen receptor (ER)-positive breast cancers resistant to the antiestrogen, tamoxifen. Methods Two cell line models of tamoxifen-resistant ER-positive breast cancer, MCF7/HER2 and BT474, showing increased AP-1 and NFκB DNA-binding and transcriptional activities, were studied to compare tamoxifen effects on NFκB and AP-1 regulated reporter genes relative to tamoxifen-sensitive MCF7 cells. The model cell lines were treated with the IKK inhibitor parthenolide (PA) or the proteasome inhibitor bortezomib (PS341), alone and in combination with tamoxifen. Expression microarray data available from 54 UCSF node-negative ER-positive breast cancer cases with known clinical outcome were used to search for potential genes signifying upregulated NFκB and AP-1 transcriptional activity in association with tamoxifen resistance. The association of these genes with patient outcome was further evaluated using node-negative ER-positive breast cancer cases identified from three other published data sets (Rotterdam, n = 209; Amsterdam, n = 68; Basel, n = 108), each having different patient age and adjuvant tamoxifen treatment characteristics. Results Doses of parthenolide and bortezomib capable of sensitizing the two endocrine resistant breast cancer models to tamoxifen were capable of suppressing NFκB and AP-1 regulated gene expression in combination with tamoxifen and also increased ER recruitment of the transcriptional co-repressor, NCoR. Transcript profiles from the UCSF breast cancer cases revealed three NFκB and AP-1 upregulated genes – cyclin D1, uPA and VEGF – capable of dichotomizing node-negative ER-positive cases into early and late relapsing subsets despite adjuvant tamoxfien therapy and most prognostic for younger age cases. Across the four independent sets of node-negative ER-positive breast cancer cases (UCSF, Rotterdam, Amsterdam, Basel), high expression of all three NFκB and AP-1 upregulated genes was associated with earliest metastatic relapse. Conclusion Altogether, these findings implicate increased NFκB and AP-1 transcriptional responses with tamoxifen resistant breast cancer and early metastatic relapse, especially in younger patients. These findings also suggest that agents capable of preventing NFκB and AP-1 gene activation may prove useful in restoring the endocrine responsiveness of such high-risk ER-positive breast cancers.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Science
  • Education
  • Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

breast, cancer, nfκb, expression, genes, gene, cells, erpositive, cases, article, google, scholar, tamoxifen, pubmed, cas, mcf, cell, mcfher, cancers, upregulated, adjuvant, activity, treatment, growth, tam, figure, age, data, reporter, therapy, levels, nodenegative, estrogen, receptor, clinical, outcome, values, years, transcriptional, prognostic, ucsf, ncor, resistance, high, significant, tamresistant, identified, relative, showed, models,

Topics {✒️}

tam-resistant er-positive/erbb2-positive models tam-sensitive er-positive/erbb2-negative models er-positive/erbb2-negative mcf7 cells er-positive/erbb2-positive subline er-positive/erbb2-positive mcf7/her2 node-negative er-positive cases er-positive/erbb2-negative mcf7 er/her2-positive breast cancer er-positive breast cancers er-positive breast cancer urokinase-type plasminogen activator phosphatidylinositol 3-kinase/akt-mediated activation open access article redox-sensitive transcription factors tamoxifen-resistant breast carcinomas b-zip transcription factors hormone-dependent breast cancers transcription factor cross-talk kaplan-meier rfs curves er-positive tumor samples minimum frozen-wet weight 54 node-negative cases cell line models er-positive mcf7 cells tam-resistant mcf7/her2 relative cut-points arbitrarily chosen 54 ucsf node-negative estrogen receptor-dependent transcription mini-complete protease inhibitors tamoxifen-resistant tumorigenic growth er-regulated gene mechanisms er dna-binding domain human breast cancer resistant breast cancer nf-kappab signaling protein a-sepharose beads firefly luminescence/renilla luminescence ncor-bound er approaching nih grants r01-ag020521 tam-sensitive mcf-7 cells ncbi/genbank geo database tam-sensitive mcf7 resulted article download pdf 3-tk-luc reporter plasmid relapsing breast cancers plasminogen activator system individual phospho-c-jun patient relapse-free survival restore er-ncor binding er-positive status

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Enhanced NFκB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer
         description:Signaling pathways that converge on two different transcription factor complexes, NFκB and AP-1, have been identified in estrogen receptor (ER)-positive breast cancers resistant to the antiestrogen, tamoxifen. Two cell line models of tamoxifen-resistant ER-positive breast cancer, MCF7/HER2 and BT474, showing increased AP-1 and NFκB DNA-binding and transcriptional activities, were studied to compare tamoxifen effects on NFκB and AP-1 regulated reporter genes relative to tamoxifen-sensitive MCF7 cells. The model cell lines were treated with the IKK inhibitor parthenolide (PA) or the proteasome inhibitor bortezomib (PS341), alone and in combination with tamoxifen. Expression microarray data available from 54 UCSF node-negative ER-positive breast cancer cases with known clinical outcome were used to search for potential genes signifying upregulated NFκB and AP-1 transcriptional activity in association with tamoxifen resistance. The association of these genes with patient outcome was further evaluated using node-negative ER-positive breast cancer cases identified from three other published data sets (Rotterdam, n = 209; Amsterdam, n = 68; Basel, n = 108), each having different patient age and adjuvant tamoxifen treatment characteristics. Doses of parthenolide and bortezomib capable of sensitizing the two endocrine resistant breast cancer models to tamoxifen were capable of suppressing NFκB and AP-1 regulated gene expression in combination with tamoxifen and also increased ER recruitment of the transcriptional co-repressor, NCoR. Transcript profiles from the UCSF breast cancer cases revealed three NFκB and AP-1 upregulated genes – cyclin D1, uPA and VEGF – capable of dichotomizing node-negative ER-positive cases into early and late relapsing subsets despite adjuvant tamoxfien therapy and most prognostic for younger age cases. Across the four independent sets of node-negative ER-positive breast cancer cases (UCSF, Rotterdam, Amsterdam, Basel), high expression of all three NFκB and AP-1 upregulated genes was associated with earliest metastatic relapse. Altogether, these findings implicate increased NFκB and AP-1 transcriptional responses with tamoxifen resistant breast cancer and early metastatic relapse, especially in younger patients. These findings also suggest that agents capable of preventing NFκB and AP-1 gene activation may prove useful in restoring the endocrine responsiveness of such high-risk ER-positive breast cancers.
         datePublished:2007-04-03T00:00:00Z
         dateModified:2007-04-03T00:00:00Z
         pageStart:1
         pageEnd:15
         license:https://creativecommons.org/licenses/by/2.0
         sameAs:https://doi.org/10.1186/1471-2407-7-59
         keywords:
            Estrogen Receptor
            Tamoxifen
            Bortezomib
            BT474 Cell
            Adjuvant Tamoxifen
            Cancer Research
            Oncology
            Surgical Oncology
            Health Promotion and Disease Prevention
            Biomedicine
            general
            Medicine/Public Health
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-7-59/MediaObjects/12885_2006_Article_709_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-7-59/MediaObjects/12885_2006_Article_709_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-7-59/MediaObjects/12885_2006_Article_709_Fig3_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-7-59/MediaObjects/12885_2006_Article_709_Fig4_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-7-59/MediaObjects/12885_2006_Article_709_Fig5_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-7-59/MediaObjects/12885_2006_Article_709_Fig6_HTML.jpg
         isPartOf:
            name:BMC Cancer
            issn:
               1471-2407
            volumeNumber:7
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Yamei Zhou
               affiliation:
                     name:Buck Institute for Age Research
                     address:
                        name:Buck Institute for Age Research, Novato, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Christina Yau
               affiliation:
                     name:Buck Institute for Age Research
                     address:
                        name:Buck Institute for Age Research, Novato, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Joe W Gray
               affiliation:
                     name:University of California
                     address:
                        name:Comprehensive Cancer Center, University of California, San Francisco, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Karen Chew
               affiliation:
                     name:University of California
                     address:
                        name:Comprehensive Cancer Center, University of California, San Francisco, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Shanaz H Dairkee
               affiliation:
                     name:California Pacific Medical Center Research Institute
                     address:
                        name:California Pacific Medical Center Research Institute, San Francisco, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Dan H Moore
               affiliation:
                     name:University of California
                     address:
                        name:Comprehensive Cancer Center, University of California, San Francisco, USA
                        type:PostalAddress
                     type:Organization
                     name:California Pacific Medical Center Research Institute
                     address:
                        name:California Pacific Medical Center Research Institute, San Francisco, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Urs Eppenberger
               affiliation:
                     name:Stiftung Tumorbank Basel
                     address:
                        name:Stiftung Tumorbank Basel, Riehen, Switzerland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Serenella Eppenberger-Castori
               affiliation:
                     name:Stiftung Tumorbank Basel
                     address:
                        name:Stiftung Tumorbank Basel, Riehen, Switzerland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Christopher C Benz
               affiliation:
                     name:Buck Institute for Age Research
                     address:
                        name:Buck Institute for Age Research, Novato, USA
                        type:PostalAddress
                     type:Organization
                     name:University of California
                     address:
                        name:Comprehensive Cancer Center, University of California, San Francisco, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Enhanced NFκB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer
      description:Signaling pathways that converge on two different transcription factor complexes, NFκB and AP-1, have been identified in estrogen receptor (ER)-positive breast cancers resistant to the antiestrogen, tamoxifen. Two cell line models of tamoxifen-resistant ER-positive breast cancer, MCF7/HER2 and BT474, showing increased AP-1 and NFκB DNA-binding and transcriptional activities, were studied to compare tamoxifen effects on NFκB and AP-1 regulated reporter genes relative to tamoxifen-sensitive MCF7 cells. The model cell lines were treated with the IKK inhibitor parthenolide (PA) or the proteasome inhibitor bortezomib (PS341), alone and in combination with tamoxifen. Expression microarray data available from 54 UCSF node-negative ER-positive breast cancer cases with known clinical outcome were used to search for potential genes signifying upregulated NFκB and AP-1 transcriptional activity in association with tamoxifen resistance. The association of these genes with patient outcome was further evaluated using node-negative ER-positive breast cancer cases identified from three other published data sets (Rotterdam, n = 209; Amsterdam, n = 68; Basel, n = 108), each having different patient age and adjuvant tamoxifen treatment characteristics. Doses of parthenolide and bortezomib capable of sensitizing the two endocrine resistant breast cancer models to tamoxifen were capable of suppressing NFκB and AP-1 regulated gene expression in combination with tamoxifen and also increased ER recruitment of the transcriptional co-repressor, NCoR. Transcript profiles from the UCSF breast cancer cases revealed three NFκB and AP-1 upregulated genes – cyclin D1, uPA and VEGF – capable of dichotomizing node-negative ER-positive cases into early and late relapsing subsets despite adjuvant tamoxfien therapy and most prognostic for younger age cases. Across the four independent sets of node-negative ER-positive breast cancer cases (UCSF, Rotterdam, Amsterdam, Basel), high expression of all three NFκB and AP-1 upregulated genes was associated with earliest metastatic relapse. Altogether, these findings implicate increased NFκB and AP-1 transcriptional responses with tamoxifen resistant breast cancer and early metastatic relapse, especially in younger patients. These findings also suggest that agents capable of preventing NFκB and AP-1 gene activation may prove useful in restoring the endocrine responsiveness of such high-risk ER-positive breast cancers.
      datePublished:2007-04-03T00:00:00Z
      dateModified:2007-04-03T00:00:00Z
      pageStart:1
      pageEnd:15
      license:https://creativecommons.org/licenses/by/2.0
      sameAs:https://doi.org/10.1186/1471-2407-7-59
      keywords:
         Estrogen Receptor
         Tamoxifen
         Bortezomib
         BT474 Cell
         Adjuvant Tamoxifen
         Cancer Research
         Oncology
         Surgical Oncology
         Health Promotion and Disease Prevention
         Biomedicine
         general
         Medicine/Public Health
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-7-59/MediaObjects/12885_2006_Article_709_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-7-59/MediaObjects/12885_2006_Article_709_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-7-59/MediaObjects/12885_2006_Article_709_Fig3_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-7-59/MediaObjects/12885_2006_Article_709_Fig4_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-7-59/MediaObjects/12885_2006_Article_709_Fig5_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-7-59/MediaObjects/12885_2006_Article_709_Fig6_HTML.jpg
      isPartOf:
         name:BMC Cancer
         issn:
            1471-2407
         volumeNumber:7
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Yamei Zhou
            affiliation:
                  name:Buck Institute for Age Research
                  address:
                     name:Buck Institute for Age Research, Novato, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Christina Yau
            affiliation:
                  name:Buck Institute for Age Research
                  address:
                     name:Buck Institute for Age Research, Novato, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Joe W Gray
            affiliation:
                  name:University of California
                  address:
                     name:Comprehensive Cancer Center, University of California, San Francisco, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Karen Chew
            affiliation:
                  name:University of California
                  address:
                     name:Comprehensive Cancer Center, University of California, San Francisco, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Shanaz H Dairkee
            affiliation:
                  name:California Pacific Medical Center Research Institute
                  address:
                     name:California Pacific Medical Center Research Institute, San Francisco, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Dan H Moore
            affiliation:
                  name:University of California
                  address:
                     name:Comprehensive Cancer Center, University of California, San Francisco, USA
                     type:PostalAddress
                  type:Organization
                  name:California Pacific Medical Center Research Institute
                  address:
                     name:California Pacific Medical Center Research Institute, San Francisco, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Urs Eppenberger
            affiliation:
                  name:Stiftung Tumorbank Basel
                  address:
                     name:Stiftung Tumorbank Basel, Riehen, Switzerland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Serenella Eppenberger-Castori
            affiliation:
                  name:Stiftung Tumorbank Basel
                  address:
                     name:Stiftung Tumorbank Basel, Riehen, Switzerland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Christopher C Benz
            affiliation:
                  name:Buck Institute for Age Research
                  address:
                     name:Buck Institute for Age Research, Novato, USA
                     type:PostalAddress
                  type:Organization
                  name:University of California
                  address:
                     name:Comprehensive Cancer Center, University of California, San Francisco, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:BMC Cancer
      issn:
         1471-2407
      volumeNumber:7
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Buck Institute for Age Research
      address:
         name:Buck Institute for Age Research, Novato, USA
         type:PostalAddress
      name:Buck Institute for Age Research
      address:
         name:Buck Institute for Age Research, Novato, USA
         type:PostalAddress
      name:University of California
      address:
         name:Comprehensive Cancer Center, University of California, San Francisco, USA
         type:PostalAddress
      name:University of California
      address:
         name:Comprehensive Cancer Center, University of California, San Francisco, USA
         type:PostalAddress
      name:California Pacific Medical Center Research Institute
      address:
         name:California Pacific Medical Center Research Institute, San Francisco, USA
         type:PostalAddress
      name:University of California
      address:
         name:Comprehensive Cancer Center, University of California, San Francisco, USA
         type:PostalAddress
      name:California Pacific Medical Center Research Institute
      address:
         name:California Pacific Medical Center Research Institute, San Francisco, USA
         type:PostalAddress
      name:Stiftung Tumorbank Basel
      address:
         name:Stiftung Tumorbank Basel, Riehen, Switzerland
         type:PostalAddress
      name:Stiftung Tumorbank Basel
      address:
         name:Stiftung Tumorbank Basel, Riehen, Switzerland
         type:PostalAddress
      name:Buck Institute for Age Research
      address:
         name:Buck Institute for Age Research, Novato, USA
         type:PostalAddress
      name:University of California
      address:
         name:Comprehensive Cancer Center, University of California, San Francisco, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Yamei Zhou
      affiliation:
            name:Buck Institute for Age Research
            address:
               name:Buck Institute for Age Research, Novato, USA
               type:PostalAddress
            type:Organization
      name:Christina Yau
      affiliation:
            name:Buck Institute for Age Research
            address:
               name:Buck Institute for Age Research, Novato, USA
               type:PostalAddress
            type:Organization
      name:Joe W Gray
      affiliation:
            name:University of California
            address:
               name:Comprehensive Cancer Center, University of California, San Francisco, USA
               type:PostalAddress
            type:Organization
      name:Karen Chew
      affiliation:
            name:University of California
            address:
               name:Comprehensive Cancer Center, University of California, San Francisco, USA
               type:PostalAddress
            type:Organization
      name:Shanaz H Dairkee
      affiliation:
            name:California Pacific Medical Center Research Institute
            address:
               name:California Pacific Medical Center Research Institute, San Francisco, USA
               type:PostalAddress
            type:Organization
      name:Dan H Moore
      affiliation:
            name:University of California
            address:
               name:Comprehensive Cancer Center, University of California, San Francisco, USA
               type:PostalAddress
            type:Organization
            name:California Pacific Medical Center Research Institute
            address:
               name:California Pacific Medical Center Research Institute, San Francisco, USA
               type:PostalAddress
            type:Organization
      name:Urs Eppenberger
      affiliation:
            name:Stiftung Tumorbank Basel
            address:
               name:Stiftung Tumorbank Basel, Riehen, Switzerland
               type:PostalAddress
            type:Organization
      name:Serenella Eppenberger-Castori
      affiliation:
            name:Stiftung Tumorbank Basel
            address:
               name:Stiftung Tumorbank Basel, Riehen, Switzerland
               type:PostalAddress
            type:Organization
      name:Christopher C Benz
      affiliation:
            name:Buck Institute for Age Research
            address:
               name:Buck Institute for Age Research, Novato, USA
               type:PostalAddress
            type:Organization
            name:University of California
            address:
               name:Comprehensive Cancer Center, University of California, San Francisco, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Buck Institute for Age Research, Novato, USA
      name:Buck Institute for Age Research, Novato, USA
      name:Comprehensive Cancer Center, University of California, San Francisco, USA
      name:Comprehensive Cancer Center, University of California, San Francisco, USA
      name:California Pacific Medical Center Research Institute, San Francisco, USA
      name:Comprehensive Cancer Center, University of California, San Francisco, USA
      name:California Pacific Medical Center Research Institute, San Francisco, USA
      name:Stiftung Tumorbank Basel, Riehen, Switzerland
      name:Stiftung Tumorbank Basel, Riehen, Switzerland
      name:Buck Institute for Age Research, Novato, USA
      name:Comprehensive Cancer Center, University of California, San Francisco, USA

External Links {🔗}(177)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

CDN Services {📦}

  • Crossref

5.21s.